CERO CERo Therapeutics Holdings Quarterly EPS earnings growth

Official company branding of cero.bio (CERO)

CERo Therapeutics relies on complex cryogenic logistics for the transport of live cells, ensuring supply chain resilience. This quarterly earnings per share chart demonstrates financial dynamics where the value of 0.00 characterizes this level. The company strives for leadership in T-cell therapy by developing methods to combat tumors, although the current phagocytosis R&D pipeline still requires linear cost growth.

CERo Therapeutics Holdings (CERO) Year-over-year earnings per share growth for the last twelve months: for the period 02/21/2024 - 11/08/2025

cero.bio (CERO) - metric breakdowns and financial figures

Fundamental company analysis:CERo Therapeutics Holdings, Inc. - CERO
Finished products of CERo Therapeutics

Analyzing the growth rates of net income per share is critical for selecting assets with a high margin of safety, as it objectively reflects operational efficiency and the real profitability trend without market distortions. In the case of CERo Therapeutics (CERO), this metric serves as a benchmark for management's ability to convert resources into results during the clinical trial launch phase, which is clearly illustrated by the quarterly EPS price action.